Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in EVAX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Merck & Co., Inc. | 1.2M | $4.5M | 0.0% | 19.221% | 1.29% |
| 2 | Ikarian Capital, LLC | 75K | $278K | 0.0% | 1.183% | 0.03% |
| 3 | Rathbone Brothers plc | 46K | $170K | β | 0.724% | 0.00% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 39K | $146K | β | 0.621% | 0.00% |
| 5 | Annis Gardner Whiting Capital Advisors, LLC | 30K | $112K | β | 0.475% | 0.02% |
| 6 | XTX Topco Ltd | 22K | $82K | β | 0.349% | 0.00% |
| 7 | RHUMBLINE ADVISERS | 22K | $81K | +2.7% | 0.343% | 0.00% |
| 8 | Stonepine Capital Management, LLC | 20K | $73K | -1.4% | 0.312% | 0.06% |
| 9 | BOOTHBAY FUND MANAGEMENT, LLC | 18K | $69K | 0.0% | 0.292% | 0.00% |
| 10 | CITADEL ADVISORS LLC | 18K | $66K | β | 0.281% | 0.00% |
| 11 | SmartHarvest Portfolios, LLC | 14K | $51K | -9.1% | 0.219% | 0.02% |
| 12 | WESBANCO BANK INC | 10K | $37K | 0.0% | 0.158% | 0.00% |
| 13 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8K | $30K | β | 0.127% | 0.00% |
| 14 | GAMMA Investing LLC | 5K | $19K | +35.3% | 0.082% | 0.00% |
| 15 | EverSource Wealth Advisors, LLC | 720 | $12K | -73.4% | 0.011% | 0.00% |
| 16 | SBI Securities Co., Ltd. | 62 | $231 | 0.0% | 0.001% | 0.00% |
| 17 | BESSEMER GROUP INC | 18 | $0 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in EVAX β a direct measure of their conviction.
Filings activity in EVAX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new EVAX position in Q1 2026
Institutions that fully closed their EVAX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 17 | +21% | 24.37% | 4.39 pp | $6M | 15% |
| Q4 2025 | 14 | +75% | 28.76% | +7.52 pp | $7M | +35% |
| Q3 2025 | 8 | 11% | 21.24% | +7.37 pp | $5M | +53% |
| Q2 2025 | 9 | 18% | 13.87% | +3.28 pp | $3M | +31% |
| Q1 2025 | 11 | +0.0% | 10.59% | +7.70 pp | $2M | +266% |
| Q4 2024 | 11 | +22% | 2.89% | 4.35 pp | $1M | 60% |
| Q3 2024 | 9 | +29% | 7.24% | +1.67 pp | $2M | +30% |
| Q2 2024 | 7 | β | 5.57% | β | $1M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying EVAX stock.
Based on Q1 2026 13F filings, institutional ownership of Evaxion Biotech A/S stands at 24.4%, held across 17 reporting institutions.
Merck & Co., Inc. is the largest reported institutional holder of EVAX, with approximately 1,214,126 shares worth $0.00B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of EVAX, including RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for EVAX is 50 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
6 institutions opened new positions in EVAX during Q1 2026, while 3 fully exited. 1 added to existing positions and 9 trimmed.
EVAX institutional ownership fell by 4.39 percentage points quarter-over-quarter, with a net change of +3 holders.
The top 10 institutions account for 97.4% of all reported 13F value in EVAX, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Evaxion Biotech A/S (EVAX) Institutional Ownership